Connection

Michael Lilly to Circulating Tumor DNA

This is a "connection" page, showing publications Michael Lilly has written about Circulating Tumor DNA.
Connection Strength

1.839
  1. Elevated serum CEA is associated with liver metastasis and distinctive circulating tumor DNA alterations in patients with castration-resistant prostate cancer. Prostate. 2022 09; 82(13):1264-1272.
    View in: PubMed
    Score: 0.831
  2. Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer. Cancer. 2019 05 01; 125(9):1459-1469.
    View in: PubMed
    Score: 0.653
  3. Circulating-tumor DNA as predictor of enzalutamide response post-abiraterone treatment in metastatic castration-resistant prostate cancer. Cancer Treat Res Commun. 2020; 24:100193.
    View in: PubMed
    Score: 0.181
  4. Comprehensive Analysis of AR Alterations in Circulating Tumor DNA from Patients with Advanced Prostate Cancer. Oncologist. 2020 04; 25(4):327-333.
    View in: PubMed
    Score: 0.173
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.